Tandem Diabetes Care (BSP:T2ND34) Cyclically Adjusted FCF per Share: R$0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:T2ND34 Tandem Diabetes Care Inc BSP:T2ND34
45 GF Score
Price R$5.80
GF Value R$9.93
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Tandem Diabetes Care Cyclically Adjusted FCF per Share?

Tandem Diabetes Care BSP:T2ND34 -6.15% 45 Cyclically Adjusted FCF per Share is R$0.00 as of Mar. 2026. GuruFocus rates BSP:T2ND34 with a GF Score™ of 45/100 and a GF Value™ of R$9.93 (Possible Value Trap). The stock has 5 warning signs investors should review.

Note: As Cyclically Adjusted FCF per Share is a main component used to calculate Cyclically Adjusted Price-to-FCF. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Tandem Diabetes Care's adjusted free cash flow per share for the three months ended in Mar. 2026 was R$0.366. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is R$0.00 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 29.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Tandem Diabetes Care was 29.20% per year. The lowest was 29.20% per year. And the median was 29.20% per year.

As of today (2026-07-27), Tandem Diabetes Care's current stock price is R$5.80. Tandem Diabetes Care's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was R$0.00. Tandem Diabetes Care's Cyclically Adjusted Price-to-FCF of today is .


Tandem Diabetes Care  (BSP:T2ND34) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Tandem Diabetes Care Cyclically Adjusted FCF per Share Related Terms


Tandem Diabetes Care Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Tandem Diabetes Care's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tandem Diabetes Care Cyclically Adjusted FCF per Share Chart

Tandem Diabetes Care Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Tandem Diabetes Care Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BSP:T2ND34 vs AVNS, IRMD, AORT: Cyclically Adjusted FCF per Share Comparison

For the Medical Devices subindustry, Tandem Diabetes Care's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tandem Diabetes Care Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Tandem Diabetes Care's Cyclically Adjusted Price-to-FCF falls into.


BSP:T2ND34
45GF Score
Tandem Diabetes Care Inc BSP:T2ND34
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tandem Diabetes Care Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Tandem Diabetes Care's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.366/330.2130*330.2130
=0.366

Current CPI (Mar. 2026) = 330.2130.

Tandem Diabetes Care Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -17.510 241.018 -23.990
201609 -21.553 241.428 -29.479
201612 -17.737 241.432 -24.259
201703 -23.003 243.801 -31.156
201706 -10.588 244.955 -14.273
201709 -11.626 246.819 -15.554
201712 -4.253 246.524 -5.697
201803 -2.330 249.554 -3.083
201806 -0.540 251.989 -0.708
201809 -0.330 252.439 -0.432
201812 0.894 251.233 1.175
201903 -0.368 254.202 -0.478
201906 -0.211 256.143 -0.272
201909 1.280 256.759 1.646
201912 0.880 256.974 1.131
202003 -2.241 258.115 -2.867
202006 0.078 257.797 0.100
202009 0.678 260.280 0.860
202012 0.921 260.474 1.168
202103 2.270 264.877 2.830
202106 1.359 271.696 1.652
202109 2.530 274.310 3.046
202112 1.212 278.802 1.435
202203 0.869 287.504 0.998
202206 -0.451 296.311 -0.503
202209 0.155 296.808 0.172
202212 0.737 296.797 0.820
202303 -2.353 301.836 -2.574
202306 -1.064 305.109 -1.152
202309 -0.405 307.789 -0.435
202312 -5.951 306.746 -6.406
202403 -0.949 312.332 -1.003
202406 -0.973 314.175 -1.023
202409 1.820 315.301 1.906
202412 0.708 315.605 0.741
202503 -5.611 319.799 -5.794
202506 -1.299 322.561 -1.330
202509 0.331 324.800 0.337
202512 -2.568 324.054 -2.617
202603 0.366 330.213 0.366

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of R$0.00 mean?
Tandem Diabetes Care (BSP:T2ND34) has a Cyclically Adjusted FCF per Share of R$0.00 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Tandem Diabetes Care and its competitors.
Is Tandem Diabetes Care's Cyclically Adjusted FCF per Share too high?
Tandem Diabetes Care's current Cyclically Adjusted FCF per Share is R$0.00. Overall, Tandem Diabetes Care has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tandem Diabetes Care's Cyclically Adjusted FCF per Share compare to AVNS and IRMD?
Tandem Diabetes Care's Cyclically Adjusted FCF per Share of R$0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Tandem Diabetes Care and its competitors. Tandem Diabetes Care's current Cyclically Adjusted FCF per Share is R$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tandem Diabetes Care stock overvalued right now?
Based on GuruFocus' analysis, Tandem Diabetes Care (BSP:T2ND34) is currently considered Possible Value Trap. The stock's GF Value™ is R$9.93, compared to a current price of R$5.80 — trading 41.6% below its estimated fair value. The current Cyclically Adjusted FCF per Share is R$0.00. Tandem Diabetes Care's overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Tandem Diabetes Care (BSP:T2ND34), the current Cyclically Adjusted FCF per Share is R$0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tandem Diabetes Care (BSP:T2ND34) Overvalued in 2026?

Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued. The current stock price of R$5.80 is trading 41.6% below its estimated GF Value™ of R$9.93. GuruFocus considers Tandem Diabetes Care to be Possible Value Trap.

Key valuation signals for BSP:T2ND34:

  • Cyclically Adjusted FCF per Share: R$0.00
  • GF Value™: R$9.93 vs. price of R$5.80 (41.6% below fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the BSP:T2ND34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tandem Diabetes Care Business Description

Other Exchanges TNDM:USA0M0F:UKTD5A:Germany
Address 12400 High Bluff Drive, San Diego, CA, USA, 92130
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
45GF Score

Get the complete analysis for BSP:T2ND34

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$5.80
Price
R$9.93
GF Value